Epidermolysis Bullosa Clinical Trial
Official title:
A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
Verified date | August 2023 |
Source | Abeona Therapeutics, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will create a skin graft, which the investigators call "LEAES," using the patient's own skin cells that have been genetically engineered in the lab to express a missing protein called type VII collagen. The corrected cells will be transplanted back to the patient.
Status | Completed |
Enrollment | 12 |
Est. completion date | March 9, 2022 |
Est. primary completion date | March 9, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years and older |
Eligibility | Inclusion Criteria: 1. Clinical diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) 2. 13 years old or older and willing and able to give assent/consent 3. Confirmation of RDEB diagnosis by immunofluorescence (IF) and electron microscopy (EM) 4. NC1[+] and mAb LH24 antibody staining negative 5. RDEB type VII collagen mutations in subject and carrier parents confirmed 6. At least 100 to 200 cm2 areas of open erosions on the trunk and/or extremities suitable for skin grafting 7. Able to undergo adequate anesthesia to allow grafting procedures to take place. Exclusion Criteria: 1. Medical instability limiting ability to travel to Stanford University Medical Center 2. The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with HIV, hepatitis B or hepatitis C, as determined by hepatitis B surface antigen screening, detection of hepatitis C antibodies, or positive result of hepatitis C polymerase chain reaction (PCR) analysis. 3. Antibodies to type VII collagen associated antigens 4. Active infection in the area that will undergo grafting 5. Evidence of systemic infection 6. Current evidence or a history of squamous cell carcinoma in the area that will undergo grafting 7. Active drug or alcohol addiction 8. Hypersensitivity to vancomycin or amikacin 9. Receipt of chemical or biological study product for the specific treatment of RDEB in the past six months 10. Positive pregnancy test or breast-feeding 11. Clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute [NCI] toxicity scale) on laboratory tests performed prior to grafting, except for the following specific exclusionary laboratory threshold results, subject to approval or exemption by the EB physician: - Albumin < 2.5 g/dL - Leukocytes > 20K/uL - Hemoglobin < 7.5 g/dL. Low hemoglobin will be treated at the discretion of the investigators and the EB physician. - Additional exceptions may be made at the discretion of the investigators and the EB physician. 12. Clinically significant abnormalities (Grade 2 or higher on the NCI toxicity scale) identified through medical history and physical examination on Day 0, with the following exceptions: - Anorexia, can enroll up to Grade 4 (inclusive) - Constipation, can enroll up to Grade 2 (inclusive) - Dysphagia, can enroll up to Grade 4 (inclusive) - Keratitis, can enroll up to Grade 4 (inclusive) - Bone pain, can enroll up to Grade 2 (inclusive) - Additional exceptions may be made at the discretion of the investigators and the EB physician. |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University, School of Medicine, Dept of Dermatology | Redwood City | California |
Lead Sponsor | Collaborator |
---|---|
Abeona Therapeutics, Inc | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Participants With Presence of Anchoring Fibrils (AF) | Skin biopsies were obtained to observe physical development of the anchoring fibrils using electron microscopy | 3 months, 6 months, 12 months and 24 months post grafting | |
Primary | Number of Wounds by Healing Category Per Investigator Visual Assessment | The graft site was clinically evaluated by the investigator with a global score of: 1) 100% to 75% healed, 2) 74% to 50% healed, 3) 49% or less healed with 100% meaning completely healed. | 3, 6, 12 and 24 months post grafting | |
Primary | Percentage Surface Area of Wound Healing | Percentage of wound area will be obtained using the Canfield system. Changes in dimensions between visits as well as changes in dimensions from baseline will be recorded. Dimensions of untreated wounded skin will be used for comparison | 3, 6 and 12 months post grafting | |
Secondary | Number Participants Positive for NC2 Epitope as a Measure of Duration of Type VII Collagen Production | Skin biopsies were obtained to evaluate expression of type VII collagen, NC2 epitope, using immuno-electron microscopy and immuno-fluorescent light microscopy. | 3 months, 6 months, 12 months, 24 months post-grafting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00380640 -
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT00004761 -
Establishment of the National Epidermolysis Bullosa Registry
|
N/A | |
Completed |
NCT01716169 -
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
|
N/A | |
Withdrawn |
NCT01454687 -
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes
|
N/A | |
Completed |
NCT00014729 -
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
Recruiting |
NCT05838092 -
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
|
Phase 3 | |
Recruiting |
NCT03269474 -
Computational Drug Repurposing for All EBS Cases
|
||
Completed |
NCT03068780 -
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT02090283 -
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT02582775 -
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
|
Phase 2 | |
Recruiting |
NCT04213703 -
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
|
||
Completed |
NCT02384460 -
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT02670330 -
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT01619670 -
A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa
|
Phase 4 | |
Recruiting |
NCT01340235 -
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
|
Phase 3 | |
Completed |
NCT02014376 -
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT04217538 -
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
|
||
Completed |
NCT03942250 -
Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients
|
N/A | |
Completed |
NCT01033552 -
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
|
Phase 1/Phase 2 | |
Completed |
NCT04227106 -
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 3 |